This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davids, V.
Right arrow Articles by Kaplan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davids, V.
Right arrow Articles by Kaplan, G.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2007, p. 198-200, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00309-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Dose-Dependent Immune Response to Mycobacterium bovis BCG Vaccination in Neonates{triangledown}

Virginia Davids,1 Willem Hanekom,1 Sebastian J. Gelderbloem,1 Anthony Hawkridge,1 Gregory Hussey,1 Ronel Sheperd,1 Lesley Workman,1 Jorge Soler,2 Rose Ann Murray,2 Stanley R. Ress,3 and Gilla Kaplan2*

South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa,1 The Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey,2 Division of Clinical Immunology, Department of Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa3

Received 24 August 2006/ Returned for modification 20 November 2006/ Accepted 8 December 2006

In 10-week-old infants vaccinated at birth with Japanese Mycobacterium bovis BCG, the number of dermal needle penetrations correlated positively with frequency of proliferating CD4+ T cells in whole blood following BCG stimulation for 6 days but did not correlate with secreted cytokine levels after 7 h or interferon CD4+ T-cell frequency after 12 h of BCG stimulation.

* Corresponding author. Mailing address: The Public Health Research Institute, Laboratory of Mycobacterial Immunity and Pathogenesis, 225 Warren St., Newark, NJ 07103-3535. Phone: (973) 854-3220. Fax: (973) 854-3222. E-mail: kaplan{at}phri.org.

{triangledown} Published ahead of print on 20 December 2006.

Clinical and Vaccine Immunology, February 2007, p. 198-200, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00309-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hawkridge, A., Hatherill, M., Little, F., Goetz, M. A., Barker, L., Mahomed, H., Sadoff, J., Hanekom, W., Geiter, L., Hussey, G., the South African BCG trial team, (2008). Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337: a2052-a2052 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»